معرفی
Marcus Järås is an Associate Professor and Senior Lecturer at Lund University's Division of Clinical Genetics. He serves as Research Team Manager for Targeted Therapies in Leukemia, Principal Investigator at the Lund University Cancer Centre (LUCC), and Principal Investigator in the StemTherapy National Initiative on Stem Cells for Regenerative Therapy. His academic roles reflect a focus on translational cancer research.
- Lund University Cancer Centre (LUCC)
- StemTherapy National Initiative
- Division of Clinical Genetics
Research Interests: Dr. Järås specializes in targeting innate immune checkpoints in acute myeloid leukemia (AML). His work uses CRISPR screens to identify cell surface proteins that protect AML cells from immune attack and evaluates their therapeutic potential through in vivo models. Key areas include leukemia stem cell biology, immune evasion mechanisms, and development of antibody-based immunotherapies.
Publication Trends: Recent work explores metabolic vulnerabilities in AML, niche protection of leukemia stem cells, and complement receptor targeting. Earlier studies established the therapeutic value of IL1RAP antibodies, combining CRISPR technology with xenograft models.
Leadership & Collaboration: He supervises PhD students, co-organizes LUCC conferences, and chairs sessions at cancer research meetings. Collaborations span multiple institutions including the Swedish Research Council and international networks.
